IV Cocaine Abuse: A Laboratory Model - 1

This study has been completed.

First Received on September 20, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Columbia University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000212

Purpose

The purpose of this study is to evaluate the effects of desipramine DMI maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Desipramine	Phase II

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	IV Cocaine Abuse: A Laboratory Model

Resource links provided by NLM:

Drug Information available for: Desipramine Cocaine hydrochloride Desipramine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Amount cocaine self-administered
Direct cocaine effects (cardiovascular, subjective
Interaction of cocaine and DMI on cardio measures
Interaction of cocaine/DMI on coc's subjective
Effects of DMI on cocaine craving
Drug use during outpatient DMI maintenance

Estimated Enrollment:	0
Study Start Date:	July 1987

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000212

Locations

United States, New York
Columbia University
New York, New York, United States, 10023

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Columbia University

Investigators

Principal Investigator:

Richard Foltin, Ph.D.

Columbia University

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000212 History of Changes
Other Study ID Numbers:	NIDA-06234-1, R01-06234-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Desipramine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Antidepressive Agents

Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Adrenergic Uptake Inhibitors
Adrenergic Agents
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 09, 2012